Completed peer reviews since:
June 5, 2020
Drug Target Insights (DTI) covers its operating costs mainly through Article Processing Charges (APC) for accepted articles.
Other sources of revenue may include reprints and rights, supplements, digital advertising and agreement with scientific societies. All sources of financial support are approved by the Editor in Chief and any content which is not editorial is handled separately. Sponsors do not have any influence on editorial policies or decisions, which are under the responsibility of editors and peer-reviewers.